Home › Funds › Soleus Capital Management, L.P. › INBX
Soleus Capital Management, L.P. position in INBX
INHIBRX BIOSCIENCES INC · Health Care
Soleus Capital Management, L.P. reported holding 210,000 shares of INBX (INHIBRX BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$21.0M, representing 0.75% of its reported portfolio and ranking #31 among its reported holdings. Soleus Capital Management, L.P. has disclosed INBX holdings in 7 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Soleus Capital Management, L.P.'s INBX position evolved
Soleus Capital Management, L.P. first disclosed a stake in INBX in Q3 2023 at 549,183 shares (US$10.1M). The position peaked in Q3 2026 at 210,000 shares, worth US$21.0M. Across 7 filings, Soleus Capital Management, L.P. increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 210,000 shares valued at US$21.0M. Notable position changes include a 97% trim in Q4 2023, a 1686% increase in Q1 2024, a 424% increase in Q1 2026 (shares rose 41% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 549.18K | $10.08M | New |
| Q4 2023 | 15.00K | $570.00K | Reduce |
| Q1 2024 | 267.87K | $9.36M | Add |
| Q2 2024 | 88.47K | $1.25M | Reduce |
| Q4 2025 | 25.00K | $1.98M | New |
| Q1 2026 | 131.00K | $8.81M | Add |
| Q3 2026 | 210.00K | $21.02M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About INBX and 13F data
INBX (INHIBRX BIOSCIENCES INC) is a Health Care company. 40 other funds we track also report a position in INBX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$129.3M), Sanofi (US$115.9M), Schonfeld Strategic Advisors LLC (US$82.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding INBX
- PERCEPTIVE ADVISORS LLC 1.29M sh · $129.35M · Q3 2026
- Sanofi 1.16M sh · $115.89M · Q3 2026
- Schonfeld Strategic Advisors LLC 827.28K sh · $82.79M · Q3 2026
- Sofinnova Investments, Inc. 391.62K sh · $39.19M · Q3 2026
- Parkman Healthcare Partners LLC 360.26K sh · $36.05M · Q3 2026
- PFM Health Sciences, LP 320.33K sh · $32.06M · Q3 2026
- First Turn Management, LLC 171.51K sh · $17.16M · Q3 2026
- Trails Edge Capital Partners, LP 170.00K sh · $17.01M · Q3 2026
- Cormorant Asset Management, LP 50.00K sh · $5.00M · Q3 2026
More on Soleus Capital Management, L.P.
FAQ
How long has Soleus Capital Management, L.P. held INBX?
Soleus Capital Management, L.P. has disclosed INBX holdings in 7 of the last 13 reported quarters, going back to Q3 2023.
What is Soleus Capital Management, L.P.'s current position in INBX?
As of Q3 2026, Soleus Capital Management, L.P. holds 210.00K shares of INBX (INHIBRX BIOSCIENCES INC), valued at $21.02M, representing 0.75% of its reported portfolio and ranking #31.
Has Soleus Capital Management, L.P. been buying or selling INBX?
In the latest 13F filing (Q3 2026), Soleus Capital Management, L.P. newly opened its position in INBX. The position peaked in Q3 2026 at 210.00K shares.
Which other funds hold INBX?
Other major institutional holders of INBX include PERCEPTIVE ADVISORS LLC, Sanofi, Schonfeld Strategic Advisors LLC, among 40 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.